New drug aims to wipe out lingering lymphoma cells after remission

NCT ID NCT07507318

Not yet recruiting Disease control Sponsor: Rong Tao Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 19, 2026 · Updated 11 times

Summary

This study tests a drug called chidamide in people with a type of lymphoma (double-expressor DLBCL) who are in remission after initial treatment but still have tiny amounts of cancer DNA in their blood. The goal is to see if taking chidamide pills can clear this hidden disease and keep the cancer from coming back. About 69 adults will take the drug for up to 2 years, with regular monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 20000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA